OmniNano Pharmaceuticals develops dual-mechanism nanomedicines engineered to overcome the dense tumor microenvironment that impedes treatment efficacy in solid tumors. Their lead candidate, ONP-001, is a micelle that co-delivers chemotherapy and a stroma-modulating agent. This approach remodels the tumor microenvironment, enhancing drug penetration and improving outcomes for difficult-to-treat cancers like pancreatic cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis and limited treatment options. Existing therapeutic strategies often struggle with drug delivery efficiency and overcoming tumor resistance mechanisms, leading to suboptimal patient outcomes.
Solution
OmniNano Pharmaceuticals is developing a novel nano-drug delivery platform designed to co-deliver two therapeutic agents with distinct mechanisms of action. This platform utilizes polymeric micelles to encapsulate these agents, aiming to enhance drug accumulation at the tumor site and improve therapeutic efficacy while mitigating systemic toxicity. The lead candidate, ONP-001, targets pancreatic cancer by delivering an FDA-approved chemotherapeutic agent alongside a compound that depletes cancer stem cells and modulates the tumor microenvironment to overcome resistance. This dual-agent approach is designed to improve drug delivery and enhance antitumor activity in preclinical models.
Target Audience
The primary target audience includes oncologists, pharmaceutical companies, and clinical researchers focused on oncology, particularly those specializing in gastrointestinal cancers and novel drug delivery systems.
Features
- Patented nano-drug delivery platform utilizing polymeric micelles for co-delivery of two therapeutic agents.
- Encapsulation of an FDA-approved chemotherapeutic agent and a novel compound targeting cancer stem cells and tumor stroma.
- Designed to enhance drug accumulation and overcome resistance mechanisms in solid tumors.
- Lead candidate ONP-001 is in development for pancreatic ductal adenocarcinoma (PDAC).
- Preclinical data demonstrates significant antitumor activity and improved drug delivery efficiency.